Published: 25 July 2024
Author(s): Andrés J. Muñoz Martín, Javier Soto Alsar, Laura Ortega Morán
Section: Commentary

Although direct oral anticoagulants (DOACs) have been established as an effective option for cancer-associated thrombosis (CAT), there are still concerns about their safety in patients with gastrointestinal (GI) tumours, where they appear to carry a higher risk of bleeding than low-molecular-weight heparin (LMWH). Randomized clinical trials (RCTs) with DOACs in CAT have yielded conflicting results regarding the risk of bleeding in GI cancer. In the HOKUSAI VTE Cancer trial, patients with gastrointestinal cancer had a significantly higher risk of major bleeding when treated with edoxaban compared to dalteparin (HR 4.0, 95 % confidence interval 1.5 to 10.6, p = 0.005).

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness